Study guide
9.5 Sleep-Disordered Breathing in Cardiac Patients
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
9.5 Sleep-Disordered Breathing in Cardiac Patients
Key Takeaways Explain This Topic AI
Apnea-hypopnea index severity bands are normal under 5, mild 5-14.9, moderate 15-29.9, and severe 30 or more; obstructive events show continued respiratory effort while central events show none.
Adaptive servo-ventilation is contraindicated in symptomatic HFrEF with an ejection fraction of 45% or less and predominant central sleep apnea, because SERVE-HF showed increased all-cause and cardiovascular mortality; CPAP for obstructive apnea in heart failure is not affected by this rule.
Untreated obstructive sleep apnea roughly doubles atrial fibrillation recurrence after cardioversion and lowers ablation success, and it is present in 70-80% of patients with resistant hypertension.
Hypoxia-triggered vagal surges cause nocturnal sinus pauses and high-grade AV block that resolve with CPAP - evaluate for OSA before implanting a pacemaker for sleep-related bradyarrhythmia.
CPAP adherence is defined as at least 4 hours per night on 70% or more of nights over 30 consecutive days, and supplemental oxygen alone raises the SpO2 nadir while apneas, arousals and CO2 retention continue.
Last updated: August 2026
Why Sleep-Disordered Breathing Is a Cardiac Diagnosis
Test-plan item II.A.5 is placed under non-cardiovascular conditions, but on CMC it is asked as a cardiac question: sleep-disordered breathing is one of the most prevalent, most under-recognized and most modifiable contributors to resistant hypertension, atrial fibrillation recurrence, nocturnal bradyarrhythmia, pulmonary hypertension and heart failure decompensation. Roughly half of patients with heart failure have clinically significant sleep-disordered breathing, and the majority of them have never been tested.
Definitions and Severity
Apnea: cessation of airflow for 10 seconds or longer.
Hypopnea: a reduction in airflow of 30% or more for 10 seconds or longer with an associated desaturation (3-4%, depending on scoring rules) or arousal.
Apnea-Hypopnea Index (AHI): events per hour of sleep. Normal under 5; mild 5-14.9; moderate 15-29.9; severe 30 or more.
The Three Patterns
Feature Obstructive sleep apnea (OSA) Central sleep apnea (CSA), non-Cheyne-Stokes Cheyne-Stokes respiration (CSA-CSR)
Mechanism Repetitive pharyngeal collapse with continued respiratory effort Loss or instability of central respiratory drive High loop gain: hypersensitive chemoreceptors plus prolonged circulation time from low cardiac output
Respiratory effort during the event Present and increasing , with paradoxical thoraco-abdominal motion Absent Absent during apneas, with crescendo-decrescendo tidal volume between them
Typical breathing pattern Snoring, gasping, witnessed apneas, choking arousals Abrupt apneas without a crescendo pattern Smooth waxing-waning pattern with a long cycle length, typically 60 seconds or more
Typical population Obesity, neck circumference above 43 cm (17 inches) in men, retrognathia, male sex, resistant hypertension, atrial fibrillation Chronic opioid use, high altitude, stroke and brainstem lesions, treatment-emergent (complex) apnea on PAP HFrEF, especially EF below 40% , atrial fibrillation, low cardiac output; present in roughly 25-40% of HFrEF
PaCO2 Normal, or elevated if obesity hypoventilation coexists May be elevated (hypercapnic CSA) or low Low-normal to low — hyperventilation drives PaCO2 below the apneic threshold
Cardiac significance Resistant hypertension, AF and AF recurrence, nocturnal bradyarrhythmia, pulmonary hypertension, worse HF outcomes Marker of the underlying neurologic, pharmacologic or cardiac disorder Independent marker of heart failure severity and mortality
First-line management CPAP plus weight and positional measures Treat the cause; taper opioids; address altitude or PAP settings Optimize heart failure therapy first ; adaptive servo-ventilation is contraindicated when EF is 45% or less
How OSA Damages the Cardiovascular System
Five mechanisms, all testable:
Intrathoracic pressure swings. Inspiratory effort against a closed airway (a repeated Muller maneuver) generates intrathoracic pressures of -40 to -80 cmH2O. This raises LV transmural pressure and therefore LV afterload , increases venous return to the right heart, shifts the septum leftward, and stretches the atria. Repeated atrial stretch is a direct driver of atrial remodeling and atrial fibrillation .
Intermittent hypoxemia and reoxygenation produce oxidative stress, reduced nitric oxide bioavailability, endothelial dysfunction and accelerated atherosclerosis — a pattern more injurious than sustained hypoxemia.
Sympathetic surges at each arousal cause nocturnal blood pressure spikes, a non-dipping or reverse-dipping 24-hour pattern, an exaggerated morning surge, and elevated daytime catecholamines. OSA is the single most common identifiable cause of resistant hypertension , present in roughly 70-80% of patients with resistant hypertension.
Systemic inflammation and metabolic dysregulation — elevated CRP and IL-6, insulin resistance, and worsened glycemic control.
Hypoxia-triggered vagal surges (the diving reflex) produce nocturnal sinus pauses and high-grade AV block that resolve with CPAP. This is a classic exam item: nocturnal bradyarrhythmias in a snoring, obese patient warrant evaluation for OSA before a permanent pacemaker is implanted.
Downstream consequences that show up on the CMC exam: atrial fibrillation recurrence after cardioversion is roughly double in untreated OSA compared with treated patients , catheter ablation success is meaningfully lower with untreated OSA and improves with CPAP, and OSA contributes to Group 3 pulmonary hypertension, worse heart failure outcomes, stroke, and increased perioperative complications.